Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study.
Bakouni H, McAnulty C, Tatar O, Socias ME, Le Foll B, Lim R, Ahamad K, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. Bakouni H, et al. Am J Addict. 2023 Sep;32(5):469-478. doi: 10.1111/ajad.13439. Epub 2023 Jun 12. Am J Addict. 2023. PMID: 37308805 Clinical Trial.
Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder.
Enns B, Krebs E, Whitehurst DGT, Jutras-Aswad D, Le Foll B, Socias ME, Nosyk B; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. Enns B, et al. Drug Alcohol Depend. 2023 Jun 1;247:109893. doi: 10.1016/j.drugalcdep.2023.109893. Epub 2023 Apr 23. Drug Alcohol Depend. 2023. PMID: 37120920 Clinical Trial.
Les 'Lignes Directrices Pour l'Usage du Cannabis à Moindre Risque (LUCMR)': RECOMMENDATIONS [The 'Lower-Risk Cannabis Use Guidelines (LRCUG)': RECOMMENDATIONS (FRENCH)].
Fischer B, Robinson T, Bullen C, Curran V, Jutras-Aswad D, Medina-Mora ME, Pacula R, Rehm J, Room R, van den Brink W, Hall W. Fischer B, et al. Int J Drug Policy. 2023 Apr 11:103994. doi: 10.1016/j.drugpo.2023.103994. Online ahead of print. Int J Drug Policy. 2023. PMID: 37055339 No abstract available.
Las 'Guías para el Uso de Cannabis de Menor Riesgo (GUCMR)': RECOMENDACIONES [The 'Lower-Risk Cannabis Use Guidelines (LRCUG)': RECOMMENDATIONS (SPANISH)].
Fischer B, Robinson T, Bullen C, Curran V, Jutras-Aswad D, Medina-Mora ME, Pacula R, Rehm J, Room R, van den Brink W, Hall W. Fischer B, et al. Int J Drug Policy. 2023 Apr 11:103996. doi: 10.1016/j.drugpo.2023.103996. Online ahead of print. Int J Drug Policy. 2023. PMID: 37055340 No abstract available.
Sensitivity to change of generic preference-based instruments (EQ-5D-3L, EQ-5D-5L, and HUI3) in the context of treatment for people with prescription-type opioid use disorder in Canada.
Whitehurst DGT, Mah C, Krebs E, Enns B, Socias ME, Jutras-Aswad D, Le Foll B, Nosyk B; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. Whitehurst DGT, et al. Qual Life Res. 2023 Aug;32(8):2209-2221. doi: 10.1007/s11136-023-03381-6. Epub 2023 Apr 7. Qual Life Res. 2023. PMID: 37027087 Free PMC article. Clinical Trial.
139 results